Corticosteroids Flashcards

(45 cards)

1
Q

Adrenocorticoids

A

Glucocorticoids
Mineralcorticoids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Glucocorticoids

A

Stress hormones
Increase circulating glucose concentrations
Potent anti-inflammatory effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mineralocorticoids

A

Na+ retention
Increase blood volume
Increase blood pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

T/F: Epinephrine and Cortisol contrast each other

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Adrenal insufficiency other name

A

Hypoadrenalism - Decreased secretion of steroid hormones by the adrenal cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Adrenal insufficiency causes

A

Destruction of the cortex by tuberculosis or atrophy (primary: Addison’s disease)
-Decreased secretion of ACTH due to diseases of anterior pituitary (secondary; no hypoaldosteronism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Adrenal insufficiency symptoms

A

Extreme weakness
Anorexia, anemia, nausea, vomiting
Low blood pressure (in primary only)
Mental depression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cessation of long-term systemic glucocorticoid therapy can lead to

A

Addisonian symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cushing’s disease other name

A

Hyperadrenalism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Cushing’s disease causes

A

Tumors in the adrenal cortex (adrenal)
Increased production of ACTH due to non-pituitary carcinoma (pituitary)
Ectopic production of ACTH due to non-pituitary carcinoma (ectopic)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cushing’s disease causes

A

Increased protein catabolism (easy bruising, wound healing, muscle wasting) increased glucose levels
Osteoporosis
opportunistic infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Long-term therapeutic use of systemic glucocorticoids can lead to

A

Cushing’s symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Change of cortisol to cortisone

A

OH on 11 is changed to ketone on 11

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

T/F: the conversion of cortisol to cortisone is reversible

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

T/f: cortisone is effective as cortisol, when used systemically

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

T/F: Cortisone should be used in patients with impaired liver function

A

False

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Short acting systemic corticosteroids (8-12 hrs)

A

Hydrocortisone
Cortisone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Intermediate acting systemic corticosteroids (12-36hrs)

A

Prednisone
Prednisolone
Methylprednisolone
Traimcinolone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Long-acting systemic corticosteroids (36-54 hrs)

A

Dexamethasone
Betamethasone

20
Q

Fludrocortisone

A

Synthetic glucocorticoid
9a-F
Greater glucocorticoid activity
Strong mineralocorticoid activity
Intense Na+ retention leading to edema
Used in mineralocorticoid replacement therapy
(ADDITION OF F)
(intermediate)

21
Q

Prednisone/Prednisolone

A

Synthetic Glucocorticoids
Extra double bond between CI and C2
Altered ring structure
More potent glucocorticoid activity
Stronger binding to the glucocorticoid receptor
Reduced mineralocorticoid activity
Interconvertible by 11B hydroxysteroid dehydrogenase
(DOUBLE BOND ON THE TOP OF FIRST RING)
(intermediate)

22
Q

Methylprednisolone

A

Synthetic glucocorticoids
6a-methyl group
Potency similar to that for prednisolone
Reduced mineralocorticoid activity
(ADDITION OF METHYL ON CARBON 6)
(Intermediate)

23
Q

Triamcinolone

A

Synthetic glucocorticoids
9a-F and 16a-OH
Glucocorticoid activity similar to prednisone
Reduced mineralocorticoid activity
Increased hydrophilicity
Low oral bioavailability
(F AND OH)
(intermediate acting)

24
Q

Dexamethasone

A

16a-methyl group
Increased lipophilicity
Increased receptor binding
Significantly stronger effect
Increased stability in human plasma
Reduced mineralocorticoid activity
(Long duration)

25
Betamethasone
Synthetic glucocorticoid Enantiomer of dexamethasone at 16 Has similar properties as dexamethasone (Long duration)
26
21 esters properties
The hydroxyl group at 21 can be modified to an ester to control the property of glucocorticoids Prodrugs activated through hydrolysis by esterases
27
21 esters: Acetates
Acetate: Increased lipophilicity Prolonged action upon IM or intra-articular injection
28
21 esters: Succinate
Soluble Slow hydrolysis
29
21 esters: Phosphate
Increased solubility Rapid hydrolysis by phosphatases (~10 min) IV or IM injection for emergency conditions
30
Inhaled Glucocorticoids: Desired properties
High potency Minimal systemic effects Prolonged action
31
Inhaled glucocorticoids: Solutions
High lipophilicity Tighter binding to the receptor Better tissue penetration Prolonged action by forming poorly soluble microcrystals Low oral bioavailability 70-90% of inhaled glucocorticoids is swallowed Rapid Short half-life
32
Triamcinolone acetonide
Inhaled glucocorticoid: Acetonide is resistant hydrolysis 8x more potent than prednisolone (ADDITION OF STICKS)
33
Beclomethasone dipropionate
Converted rapidly to 17-monopropionate by hydrolysis 14x more potent than deamethasone
34
Flunisolide
Inhaled glucocorticoids Rapid absorption from nasal or lung tissue Rapid metabolism by the liver Extensive first-path metabolism Minimal systemic adverse effect with long-term therapy
35
Budesonide
Inhaled Glucocorticoids 1:1 mix of epimers at 16,17-butylacetal Faster topical uptake Low oral bioavailability Extensive first-path metabolism
36
Mometasone furoate
Inhaled glucocorticoids Highly potent More rapid onset of action Negligible systemic availability Rapid metabolism low oral bioavailability (<1%)
37
Fluticasone Propionate
Inhaled Glucocorticoids Inactivated by hydrolysis of thioester Rapid first-path metabolism Highly lipophilic and insoluble Highly potent Poor absorption from GI Rapid topical uptake
38
Topical Glucocorticoids desired properties
High lipophilicity for fast absorption Minimal systemic effect Prolonged action
39
T/F: Topical Glucocorticoids are Halogenated analogues
True
40
Topical Glucocorticoids examples
Triamcinolone acetonide Fluocinonide Betamethasone valerate (medium potency) Acetonide or ester forms have better potency for topical applications due to high lipophilicity
41
21-cholorocorticoids
Clobetasol propionate Halobetasol propionate Halcinonide Substitution of a chlorine atom for the 21-hydroxyl group greatly enhances topical anti-inflammatory activity
42
Fluticasone propionate and mometasone furoate have - potency
Medium, high lipophilicity and the highest binding affinity, but poor solubility Poor dissolution into inflamed tissue
43
Adverse effects of glucocorticoids: crossover mineralocorticoids activity
Sodium and water retention Development of HTN Correctable with selective synthetic glucocorticoids
44
Adverse effects of glucocorticoids: Metabolic effects (increased glucose production):
Steroid myopathy High doses over period of time cause wasting of proximal muscles Reduced long bone growth in children May cause premature closing of epiphyseal junction and stop growth Osteoporosis Pharmacological doses of glucocorticoids inhibit osteoblasts can be prevented by bisphosphonate
45
Adverse effects of glucocorticoids:
Cushing's-like effects - redistribution of fat -Moon face